Silo Pharma Granted U.S. Patent For Novel Intranasal Post-Traumatic Stress Disorder Treatment Titled "Pharmacological Prophylactics Against Stress-Induced Affective Disorders In Females"

Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that the U.S. Patent and Trademark Office (USPTO) issued an Issue Notification for our previously filed patent application (No. 17/954,864) titled "Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females."  The projected patent number is 12,239,614 and the issue date of such patent will be March 4, 2025.

The patent reinforces protection for Silo's lead asset, SPC-15, an intranasal treatment targeting post-traumatic stress disorder (PTSD). The patent includes newly added claims to U.S. Patent 11,491,120, which was issued to Silo in November 2022.